Ariens E.J. (1986) Chirality in bioactive agents and its pitfalls . Trends Pharmacol Sci7: 200-205
2.
Arnett C.D., Fowler J.S., Wolf A.P., Shiue C.Y., McPherson D.W. (1985) [18F]-N-methylspiperone: the radioligand of choice for PETT studies of the dopamine receptor in human brain. Life Sci36: 1359-1366
3.
Arnett C.D., Fowler J.S., MacGregor R R., Schlyer D.G., Wolf A.P., Langström B., Halldin C. (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L- [11C ] deprenyl. J Neurochem49: 522-527
4.
Aquilonius S-M., Bergström K., Eckernäs S.A., Hartvig P., Leenders K.L., Lundqvist H., Antoni G., Gee A., Rimland A., Uhlin J., Langström B. (1987) In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand76: 283-287
5.
Barrio J.R., Satyamurthy N., Huang S-C., Keen R.E., Nissenson C H K, Hoffman J.M., Ackerman R.F., Bahn M.M., Mazziotta J.C., Phelps M.E. (1989) 3-(2'- [18F] fluoroethyl)spiperone: in vivo biochemical and kinetic characterisation in rodents, non human primates, and humans. J Cerebr Blood Flow Metab9: 830
6.
Bartenstein P.A., Duncan J.S., Fish DR, Sawle G.V., Luthra S.K., Frackowiak R S F (1991) 11C-Diprenorphine in generalised absence seizures. J Nucl Med32: 960 (Abstract)
7.
Belliveau J.W., Kennedy D.N., McKinstry R.C., Buchbinder B.R., Weiskoff R.M., Cohen M.S., Verea J.M., Brady T.J., Rosen B.R. (1991) Functional mapping of the human visual cortex by magnetic resonance imaging. Science254: 716-719
8.
Bench C.J., Price G.W., Lammertsma A.A., Cremer J.C., Luthra S.K., Turton D., Dolan R.J., Kettler R., Dingemanse J., Da Prada M., Biziere K., McClelland G.R., Jamieson V.L., Wood N.D., Frackowiak R.S. (1991) Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol40: 169-173
9.
Blin J., Pappata S., Kiyosawa M., Crouzel C., Baron J.C. (1988) [18F ] Setoperone: a new high affinity ligand for positron emission tomography. Eur J Pharmacol147: 73-82
10.
Bottlaender M., Brouillet E., Varaste M., Sitbon R., Fournier D., Mazière B., Mazière M. (1992) In vivo interaction of triazolam with central type benzodiazepine receptors in baboons; a PET study. J Nucl Med33: 973 (Abstract)
11.
Chi D.Y., Kilbourn M.R., Katzenellenbogen J.A., Brodack J.W., Welch M.J. (1986) Synthesis of no-carrier-added N-( [18F] fluoroalkyl)-spiperone derivatives. Int J Appl Radiat Isot37: 1173-1180
12.
Chugani D.C., Ackermann R.F., Phelps M.E. (1988) In vivo [3H] spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization . J Cerebr Blood Flow Metab8: 291-303
13.
Coenen H.H., Laufer P., Stöcklin G., Wienhard K., Pawlik G., Böcher-Schwartz H.G., Heiss W.-D (1987) 3-N-(2'[18F]-fluoroethyl)-spiperone : a novel ligand for cerebral dopamine receptor studies with PET. Life Sci40: 81-88
14.
Coenen H.H., Wienhard K., Stöcklin G., Laufer P., Heboldt I., Pawlik G., Heiss W-D. (1988) PET measurement of D2 and S2 receptor binding of 3-N-(2'-18F] fluoroethylspiperone in baboon brain. Eur J Nucl Med14: 80-87
15.
Crouzel C., Guillaume M., Barré L., Lemaire C., Pike V.W. (1992) Ligands and tracers for PET studies of the 5HT system—Current status. J Nucl Med Biol19: 857-870
16.
Cunningham V.J., Pike V.W., Bailey D., Freemantle C A J, Page B.C., Jones A K P, Kensett M.J., Bateman D., Luthra S.K., Jones T. (1991) A method for studying pharmacokinetics in man at picomolar drug concentrations. Br J Clin Pharmacol32: 167-172
17.
de Paulis T., Schmidt D., Clanton J.A., Ansari M.S., Holdeman KP, Pfeffer R., Manning RG (1990a) [I123]Labelled epidepride SPECT studies of dopamine D2 receptors in man. J Nucl Med31: 779 (Abstract)
18.
de Paulis T., Schmidt D., Ansari M.S., Kessler R.M. (1990b) [18F] Fluvepride: the design and synthesis of PET ligands for the dopamine D2 receptor. J Nucl Med31: 786-787 (Abstract)
19.
de Paulis T., Bingham R., Manning R.G., Mason N.S., Ansari M.S., Schmidt D.E., Kessler R.M. (1991) Design and radiofluorination of benzamide dopamine D2 receptor ligands. In Emran A M (ed.), New trends in radiopharmaceutical synthesis, quality assurance and regulatory control. Plenum Press, New York, pp. 97-107
20.
Doble A., Martin I.L. (1992) Multiple benzodiazepine receptors: no reason for anxiety. Trends Pharmacol Sci13: 76-81
21.
Eckelman W.C. (1982) Receptor specific radiopharmaceuticals. In Ell P J, Holman B L J (eds), Computed emission tomography. Oxford University Press, p. 263
22.
Farde L., Ehrin E., Eriksson L., Greitz T., Hall H., Hedstrom C-G., Litton J-E., Sedvall G. (1985) Substituted benzamides as ligands for visualization of dopamine receptors in the human brain by positron emission tomography. Proc Natl Acad Sci USA82: 3863-3867
23.
Farde L., Hall H., Ehrin E., Sedvall G. (1986) Quantitative analysis of dopamine D2 receptor binding in the living brain by positron emission tomography. Science231: 258-261
24.
Farde L., Halldin C., Stone-Elander S., Sedvall G. (1987a) PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology92: 278-284
25.
Farde L., Wiesel F-A., Hall H., Halldin C., Stone Elander S., Sedvall G. (1987b) No D2 receptor increase in PET study of schizophrenia . Arch Gen Psychiatr44: 671-672Farde L., Wiesel F-A., Halldin C., Sedvall G. (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatr45: 71-78
26.
Farde L., Eriksson L., Blomquist G., Halldin C. (1989a) Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J Cerebr Blood Flow Metab9: 696-708
27.
Farde L., Wiesel F-A., Nordström A.L., Sedvall G. (1989b) D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology99: S28-S31
28.
Farde L., Wiesel F-A., Stone-Elander S., Halldin C., Nordström A-L., Hall H., Sedvall G. (1990) D2 Dopamine receptors in neuroleptic-naive schizophrenic patients—a PET study with [11C]raclopride. Arch Gen Psychiatr47: 213-219
29.
Farde L., Nordström A-L., Wiesel F-A., Pauli S., Halldin C., Sedvall G. (1992) Positron emission tomography analysis of central D1 and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine— relation to extrapyramidal side effects. Arch Gen Psychiatr49: 538-544
30.
Firnau G., Garnett E.S., Chirakal R., Sood S., Nahmias C., Schrobilgen G. (1986) [18F] Fluoro-L-dopa for the in vivo study of intracerebral dopamine. Appl Radiat Isot37: 669-676
31.
Fowler J.S., Wolf A.P. (1986) 2-Deoxy-2- [18F] fluoro-D-glucose for metabolic studies: current status. Appl Radiat Isot37: 663-668
32.
Fowler J.S., MacGregor R R., Wolf A.P., Arnett C.D., Dewey S.L., Schlyer D., Christman D., Logan J., Smith M., Sachs H., Aquilonius S.M., Bjurling P., Halldin C., Hartvig P., Leenders K.L., Ludqvist H., Oreland L., Stalnacke C-G., Långström B. (1987) Mapping human brain monoamine oxidase A and B with 11C-labelled suicide inactivators and PET. Science235: 481-485
33.
Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R R., Hitzemann R., Logan J., Bendriem B., Gatley J., Christman D. (1989) Mapping cocaine binding sites in human and baboon brain in vivo. Synapse4: 371-377
34.
Fowler J.S., Volkow N.D., Logan J., MacGregor R R., Wang G-J., Wolf A.P. (1992) Alcohol intoxication does not change the distribution and kinetics of cocaine in human brain and heart. J Nucl Med33: 946 (Abstract)
35.
Frost J.J., Wagner H.N., Dannals R.F., Ravert H Y T, Limbs J.M., Wilson A.A., Burns H.D., Wong D.F. (1985) Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr9: 231-236
36.
Gibson R.E., Eckelman W.C., Rzeszotarski W.J., Jiang V., Mazaitis A., Paik C., Komai T., Reba R.C. (1979) Radiotracer localization by receptor-ligand interactions . In Colombetti L G (ed.), Principles of pharmacology Vol. II. CRC Press, Boca Raton, FL, USA, p. 17
37.
Halldin C. (1991) Radioligands for dopamine receptor PET studies: benzamides and ligands for the dopamine D-1 receptors. In Baron J C, Comar D, Farde L, Martinot J L, Mazoyer B (eds), Brain dopaminergic systems with positron tomography. Kluwer Academic Publishers, Netherlands, pp. 23-38
38.
Halldin C., Stone-Elander S., Farde L., Ehrin E., Fasth K-J., Långström B., Sedvall G. (1986) Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography . Appl Radiat Isot37: 1039-1043
39.
Halldin C., Farde L., Hogberg T., Hall H., Ohlberger A., Solin O. (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding . Nucl Med Biol18: 871-881
40.
Halldin C., Farde L., Litton J.E., Hall H., Sedvall G. (1992) [11C] Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography. Psychopharmacology108: 16-22
41.
Hamacher K., Coenen HH, Stöcklin G. (1986) N.c.a. radiofluorination of spiperone and N-methylspiperone via aminopolyether supported direct nucleophilic substitution. J Label Compounds Radiopharm23: 1047 (Abstract)
42.
Hansch C., Leo A.J. (1979) The FRAGMENT method of calculating partition coefficients. In Substituent constants for correlation analysis in chemistry and biology . John Wiley, New York, pp. 18-43
43.
Hansch C., Bjorkroth J.P., Leo A. ( 1987) Hydrophobicity and central nervous system agents: the principle of minimal hydrophobicity in drug design. J Pharm Sci76: 663-687
44.
Jones A K P, Luthra S.K., Pike V.W., Herold S., Brady F. (1985) New labelled ligand for in-vivo studies of opioid physiology. Lancetii: 665-666
45.
Jones A K P, Luthra S.K., Mazière B., Pike V.W., Loc'h C., Crouzel C., Syrota A., Jones T. (1988) Regional cerebral opioid receptor studies with [11C] diprenorphine in normal volunteers. J Neurosci Methods23: 121-129
46.
Jones A K P, Friston K.J., Qi L.Y., Harris M., Cunningham V.J., Jones T., Feinman C., Frackowiak R S J (1991) Sites of action of morphine in the brain. Lancetii: 338, 825
47.
Jones A K P, Kawa S K H, Fujiwara T., Li Q., Luthra S.K., Ashburner J., Osman S., Jones T. (1992) Quantification of 11C-diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse dose and tracer alone protocols. J Cerebr Blood Flow Metab (in press)
48.
Kilbourn M.R. (1990) Fluorine-18 labelling of radiopharmaceuticals. Nuclear Science Series NAS-NS3203, National Academy Press , Washington DC
49.
Lannoye G.S., Moerlein S.M., Parkinson D., Welch M.J. (1990) N-Fluoroalkylated and N-alkylated analogues of the dopaminergic D-2 receptor antagonist raclopride. J Med Chem33: 2430-2437
50.
Lee M.C., Wagner H.N., Tanada S., Frost J.J., Bice A.N., Dannals R.F. (1988) Duration of occupancy of opiate receptors by naltrexone . J Nucl Med29: 1207-1211
51.
Leenders K.L., Aquilonius S.M., Bergström K., Bjurling P., Crossman A.R., Eckernås S.A., Gee A., Hartvig P., Lundquist H., Langström B., Rimland A., Tedroff J. (1988) Unilateral MPTP lesion in a rhesus monkey, effect on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res445: 61-67
52.
Leo A., Hansch C., Elkins D. (1971) Partition coefficients and their uses. Chem Rev71: 525-616
53.
Leysen J.E., Gommeren W. (1984) The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D receptor, application of an original filter method. J Receptor Res4: 817-845
54.
Litton J., Farde L., Neiman J., Halldin C., Sedvall G. (1991) Positron emission tomography of benzodiazepine receptors binding in alcoholics—equilibrium quantification. J Cerebr Blood Flow Metab11 (Suppl.): 617
55.
Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R R., Hitzmann R., Bendriem B., Gatley S.J., Christman DR (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-methyl-11C]-(-)cocaine PET studies in human subjects. J Cerebr Blood Flow Metab10: 740-747
56.
London E.R., Fanelli R., Sziksy M., Jasinski D. (1987) Effects of opioid analgesics on local cerebral glucose utilization. In Holladay J, Law P-Y, Henz A (eds), Progress in opioid research. NIDA Research monograph 75. pp. 379-381
57.
Luthra S.K., Pike V.W., Brady F. (1985) The preparation of carbon-11 labelled diprenorphine: a new radioligand for the study of the opiate receptor system in vivo. J Chem Soc Chem Commun1423-1425
58.
Luthra S.K., Turton DR, Dowsett K., Bateman D.M., Kensett M.J., Waters S.L., Pike V.W. (1989) Improved and automated one-pot radiosynthesis of [11C] diprenorphine and [11C] buprenorphine. J Label Compounds Radiopharm30: 258-259 (Abstract)
59.
Mazière B., Coenen H.H., Halldin C., Någren K., Pike V.W. (1992) PET radioligands for dopamine receptors and reuptake sites: chemistry and biochemistry. Nucl Med Biol19: 497-512
60.
Mazoyer B.M. (1991) Investigation of the dopamine system with positron emission tomography: general issues in modelling. In Baron J C, Comar D, Farde L, Martinot J L, Mazoyer B (eds), Brain dopaminergic systems: imaging with positron tomography. Kluwer Academic Publishers , Netherlands, pp. 181-189
61.
Moerlein S.M., Laufer P., Stöcklin G. (1985) Effect of lipophilicity on the in vivo localization of radiolabelled spiperone analogues. Int J Nucl Med12: 353-356
62.
Nordström A-L. (1991) Measurement of dopamine receptor occupancy; clinical issues. In Baron J C, Comar D, Farde L, Martinot J L, Mazoyer B (eds), Brain dopaminergic systems: imaging with positron tomography . Kluwer Academic Publishers, Netherlands, pp. 191-198
63.
Nordström A-L., Farde L., Halldin C. (1992a) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology106: 433-438
64.
Nordström A-L., Farde L., Wiesel F-A., Orslund K., Halldin C., Uppfeldt G. (1992b) D2-Dopamine receptor occupancy and antipsychotic effect in raclopride treated schizophrenics. Ann Univ Turkuensis SerD88: A97-A98 (Abstract)
65.
Nyberg S., Farde L., Halldin C., Eriksson B. (1992a) PET examination of central D2 dopamine and 5HT2 receptor occupancy by risperidone. CINP XVIIIth Congress, Nice, July 1992
66.
Nyberg S., Farde L., Halldin C., Eriksson L., Eriksson B. (1992b) Determination of 5-HT2 receptor occupancy in the living human brain [11C] NMSP—a PET study with risperidone . Submitted to 2nd International Symposium on Serotonin from Cell Biology to Pharmacology and Therapeutics, Houston , USA, September 1992
67.
Ogawa S., Tank T.W., Menon R., Ellerman J.R., Kim S-G., Merkle H., Uginbil K. (1992) Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA:89: 5951-5955
68.
Pauli S., Farde L., Halldin C., Sedvall G. (1992) Benzodiazepine receptor occupancy during benzodiazepine treatment measured by PET in the living brain. Ann Univ Turkuensis SerD88: A101-A102
69.
Persson A., Ehrin E., Eriksson L., Farde L., Hedström C-G., Litton J-E., Mindus P., Sedvall G. (1985) Imaging of 11C-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography . J Psychiatr Res19: 609-622
70.
Pike V.W. (1988) Organic synthesis with short-lived positron-emitting radioisotopes. In Jones J R (ed.), Isotopes: essential chemistry and applications II. Special Publication No 68, Royal Society of Chemistry, London, 1988, pp. 1-39
71.
Pike V.W., Halldin C., Crouzel C., Barré L., Nutt D.J., Osman S., Shah F., Turton D.R., Waters S.L. (1992) Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites—Current status . J Nucl Med Biol (in press)
72.
Rajeswaren S., Bailey DL, Hume S.P., Townsend D.W., Geissbuhler A., Young J., Jones T. (1992) 2-D and 3-D Imaging of small animals and the human radial artery with a high resolution detector for PET. IEEE Trans Med Imaging11: 386-391
73.
Sadzot B., Lemaire C., Cantineau R., Salmon E., Plenevaux A., Maquet P., Hermanne J.P., Frank G., Guillaume M. (1990) Imaging serotonin-S2 receptors in humans with PET and the selective S2 antagonist [18F] altanserine. J Nucl Med31: 1584 (Abstract)
74.
Salmon E., Brooks D.J., Leenders K.L., Turton D.R., Hume S.P., Cremer J.E., Jones T., Frackowiak R S J (1990) A two compartmental description and kinetic procedure for measuring regional cerebral [11C] nomifensine uptake using positron emission tomography. J Cerebr Blood Flow Metab10: 307-316
75.
Samson Y., Hantraye P., Baron J.C., Soussaline F., Comar C., Maziere M. (1985) Kinetics and displacement of 11C-Ro 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. Eur J Pharmacol110: 274-251
Schlyer D.J., Volkow N.D., Fowler J.S., Wolf A.P., Shiue C-Y., Dewey S.L., Bendriem B., Logan J., Raulli R., Hitzemann R., Brodie J., Alavi A.A., MacGregor R R. (1992) Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F] haloperidol. Synapse11: 10-27
78.
Sedvall G. (1991) PET scanning as a tool in clinical psychopharmacology . Triangle30: 11-20
79.
Shinotoh H., Yamasaki T., Inoue E., Itoh T., Suzuki K., Hashimoto K., Tateno Y., Ikehira H. (1986) Visualization of specific binding sites of benzodiazepine in human brain. J Nucl Med27: 1593-1599
80.
Shinotoh H., Iyo M., Yamada T., Inoue O., Susuki K., Itoh T., Fukuda H., Yamasaki T., Tateno Y., Hirayama K. (1989) Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography. Psychopharmacology99: 202-207
81.
Simonyi M., Fitos I., Visy J. ( 1986) Chirality of bioactive agents in protein binding storage and transport processes. Trends Pharmacol Sci7: 112-116
82.
Smith M., Wolf A.P., Brodie J.D., Arnett C.D., Barouche I.F., Shiue C-Y., Fowler J.S., Russel J A G, MacGregor R R., Wolkin A., Angrist B., Rotrosen J., Peselow E. (1988) Serial [18F] N-methylspiperone PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatr23: 653-663
83.
Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J-C. (1990) Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics. Nature347: 146-151
84.
Stöcklin G. (1991) Radioligands for PET studies of D2-receptors : butyrophenones and ergot derivatives. In Baron J C, Comar D, Farde L, Martinot J L, Mazoyer B (eds), Brain dopaminergic systems: imaging with positron tomography. Kluwer Academic Publishers , Netherlands, pp. 5-22
85.
Stöcklin G. (1992) Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology. Eur J Nucl Med19: 527-551
86.
Suhara T., Fukuda H., Inoue O., Itoh T., Suzukiu K., Yamasaki T., Tateno Y. (1991) Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology103: 41
87.
Testa B. (1986) Chiral aspects of drug metabolism. Trends Pharmacol Sci7: 60-64
88.
Van Tol H H M, Bunzow J.R., Guan H-C., Sunahara R.K., Seeman P., Niznik H.B., Civello O. (1991) Cloning of the gene for a human dopamine D 4 receptor with high affinity for the antipsychotic clozapine. Nature350: 610-614
89.
Van Tol H H M, Caren M.W., Guan H-C., Ohara K., Bunzow J.R., Civelli O., Kennedy J., Seeman P., Niznik H.B., Joanovic V. (1992) Multiple dopamine D4 receptor variants in the human population. Nature358: 149-152
90.
Verhoeff N P L G (1991) Pharmacological implications for neuroreceptor imaging. Eur J Nucl Med18: 482-502
91.
Volkow N.D., Fowler J.S., Logan J., Wang G-J., Hitzemann R., MacGregor R., Dewey S.L., Wolf A.P. (1992) Decreased binding of [11C] cocaine in the brain of cocaine addicts. J Nucl Med33: 888 (Abstract)
92.
Wagner HN, Burns HD, Dannals RF, Wong DF, Långstrom B., Duelfer T., Frost J.J., Ravert H.T., Links J.M., Rosenbloom S.B., Lukas S.E., Kramer A.V., Kuhar M.J. (1983) Imaging dopamine receptors in the human brain by positron tomography. Science221: 1264-1266
Wienhard K., Coenen H.H., Pawlik G., Rudolf J., Laufer P., Jovkar S., Stöcklin G., Heiss W-D. (1990) PET studies of dopamine receptor distribution using [18F ] fluoroethylspiperone ; findings in disorders related to the dopaminergic system. J Neural Transm81: 195-213
95.
Wolkin A., Barouche F., Wolf A.P., Rotrosen J., Fowler J.S., Shiue C.Y, Cooper T.B., Brodie J.D. (1989a) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatr46: 905-908
96.
Wolkin A., Brode J.D., Barouche F., Rotrosen J., Wolf A.P., Smith M., Fowler J.S., Cooper T.B. (1989b) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatr46: 482-483
97.
Wong DF, Wagner H.N. Jr, Tune L.E., Dannals RF, Pearlson G.D., Links JM, Tamminga A.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J K T, Malat J., Williams J.A., O'Tuama L.A., Snyder S.H., Kuhar M.J., Gjedde A. (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science234: 1558-1563
98.
Zijlstra S., Louwerens J.W., Buddingh J.A., Paans A M J, Visser G., Sloof C.J., Vaalburg W., Korf J. ( 1991) The assessment of central D2-dopamine receptor occupancy with positron emission tomography in long-term medicated schizophrenic patients . In Baron J C, Comar D, Farde L, Martinot J L, Mazoyer B (eds), Brain dopaminergic systems: imaging with positron tomography . Kluwer Academic Publishers, Netherlands, pp. 181-189
